Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Decreased by TIAA Trust National Association

TIAA Trust National Association cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 4.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,578 shares of the medical equipment provider’s stock after selling 415 shares during the quarter. TIAA Trust National Association’s holdings in Zimmer Biomet were worth $1,044,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Welch Group LLC boosted its position in shares of Zimmer Biomet by 42.6% in the fourth quarter. Welch Group LLC now owns 3,014 shares of the medical equipment provider’s stock worth $367,000 after buying an additional 900 shares during the period. Bridge Creek Capital Management LLC boosted its position in shares of Zimmer Biomet by 0.4% in the fourth quarter. Bridge Creek Capital Management LLC now owns 24,895 shares of the medical equipment provider’s stock worth $3,030,000 after buying an additional 107 shares during the period. PFG Advisors boosted its position in shares of Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock worth $231,000 after buying an additional 84 shares during the period. Pinnacle Associates Ltd. boosted its position in shares of Zimmer Biomet by 13.8% in the fourth quarter. Pinnacle Associates Ltd. now owns 2,298 shares of the medical equipment provider’s stock worth $280,000 after buying an additional 278 shares during the period. Finally, Quent Capital LLC boosted its position in shares of Zimmer Biomet by 21.6% in the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 92 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

NYSE ZBH opened at $130.01 on Thursday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The stock’s 50-day moving average is $126.09 and its two-hundred day moving average is $118.36. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The firm has a market cap of $26.71 billion, a P/E ratio of 26.59, a price-to-earnings-growth ratio of 2.36 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.88 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.74%. Zimmer Biomet’s payout ratio is presently 19.63%.

Analyst Ratings Changes

Several brokerages have recently commented on ZBH. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. Citigroup raised their target price on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 9th. Truist Financial lifted their price objective on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research report on Friday, February 9th. Finally, Raymond James lifted their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $139.11.

Check Out Our Latest Stock Report on Zimmer Biomet

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Recommended Stories

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.